This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mouren, X. Articles by Schwartz, F. Search for Related Content PubMed PubMed Citation Articles by Mouren, X. Articles by Schwartz, F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Study of the Antiischemic Action of EGb 761 in the Treatment of Peripheral Arterial Occlusive Disease by TcPo2 Determination

Department of Vascular Exploration, Hôpital Tenon, and IPSEN, Paris, France

Ph. Caillard, M.D.

Department of Vascular Exploration, Hôpital Tenon, and IPSEN, Paris, France

F. Schwartz, M.D.

Department of Vascular Exploration, Hôpital Tenon, and IPSEN, Paris, France

In a randomized, placebo-controlled, double-blind, parallel study of 20 patients, the anti ischemic effect of EGb 761 (Ginkgo biloba Extract) was studied by measuring the tran scutaneous partial pressure of oxygen (TcPo₂) during exercise. Transcutaneous oximetry during exercise provides a good, noninvasive estimation of local arterial perfusion and constitutes a real index of local and regional capillary perfusion.

Twenty patients between the ages of forty-four and seventy-three years suffering from claudicating atherosclerotic arterial occlusive disease in stage II according to the Leriche and Fontaine classification, diagnosed for more than a year and stable for three months, were included.

The eligible patients received placebo for fifteen days under single-blind conditions. At the end of this preinclusion period, the eligibility criteria were checked and the patients were randomized to two treatment groups. The first group received 320 mg per day of EGb 761 for four weeks and the second group received placebo. The treadmill walking test was performed under standardized conditions at the same time of day and by the same investigator.

In a comparison of the differences before and after treatment, the areas of ischemia decreased by 38% in the EGb 761 group but remained essentially stable (+5%) in the placebo group. This difference between groups is significant (F [1.18] =4.91; P=0.04) and the 95% confidence interval for the difference ranges from 0.89 to 3.87.

This study confirmed significantly the rapid antiischemic action of EGb 761 and its value in the management of peripheral arterial occlusive disease at the stage of inter mittent claudication.

Angiology, Vol. 45, No. 6, 413-417 (1994)
DOI: 10.1177/000331979404500601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?